Immunogenicity of Ty-VLP bearing a CD8+ T cell epitope of the CS protein of P. yoelii: Enhanced memory response by boosting with recombinant vaccinia virus

Vaccine

Volumn 18, Issue 17, 2000, Pages 1863-1869

  Oliveira Ferreira, J ^a   Myahira, Y ^b   Layton, G T ^c   Savage, N ^c   Esteban, M ^d   Rodriguez, D ^d   Rodriguez, J R ^d   Nussenzweig, R S ^b   Zavala, F ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

^d CSIC   (Spain)

Author keywords

CTL response; P. yoelii; Ty virus like particles

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; SPOROZOITE; T LYMPHOCYTE; VACCINIA;

ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; EPITOPES; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LIVER; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM YOELII; PROTOZOAN PROTEINS; RETROELEMENTS; RNA, RIBOSOMAL; SPLEEN; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0033997173     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00344-8     Document Type: Article

References (33)

1. Nussenzweig V., Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45:1989;283-334.
2. + T cells to sporozoites-induced protection against malaria. Immunology. 80:1993;1-5.
3. + T cells in immunity to malaria sporozoites. J. Immunol. 151:1993;2690-2698.
4. Tsuji M., Eyster C.L., O'Brien R.L., Born W.K., Bapna M., Reichel M., Nussenzweig R.S., Zavala F. Phenotypic and functional properties of murine γδ T cell clones derived from malaria immunized, αβ T cell-deficient mice. Int. Immunol. 8:1996;359-366.
5. + T lymphocytes is required for protective immunity against Plasmodium berghei. J. Immunol. 156:1996;3374-3381.
6. + T cells and antibodies required for immunity to malaria sporozoites. Nature (London). 330:1987;664-666.
7. + T cells (Cytotoxic/supressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. USA. 85:1988;573-579.
8. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (London). 341:1989;323-326.
9. Weiss W.R., Berzofsky J.A., Houghten R.A., Sedegah M., Hollingdale M., Hoffman S.L. A T cell clone directed at circumsporozoite protein, which protects against Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149:1992;2103-2109.
10. + cytotoxic T cell clone recognizing sporozoite surface protein 2. Infect. Immun. 62:1994;2979-2983.
11. + T cell mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA. 90:1993;5214-5218.
12. + T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:1994;4636-4648.
13. + T cell-mediated protective immunity against malaria. J. Immunol. 158:1997;1268-1274.
14. Lanar D.E., Tine J.A., Taisne C., Seguin M.C., Cox W.I., Winslow J.P., Ware L.A., Kauffman E.B., Gordon D., Ballou W.R., Paoletti E., Sadoff J.C. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against malaria. Infect. Immun. 64:1996;1666-1671.
15. Sedegah M., Hedstrom R.C., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA. 88:1994;2726-2730.
16. + cytotoxic T cells. J. Exp. Med. 172:1990;1083-1090.
17. Sadoff J., Ballou W., Baron L., Majarian W., Brey R., Hockmeyer W., Cryz S., Ou J., Lowell G., Chulay J. Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 240:1998;336-338.
18. + T-cell protective immunity induced by immunization with Plasmodium berghei CS protein derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol. Lett. 46:1995;199-205.
19. Allsopp C.E.M., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., Dougan G., Hioe C., Nixon D., Paoletti E., Layton G., Hill A.V.S. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 26:1996;1951-1959.
20. Adams S.E., Dawson K.M., Gull K., Kingsman S.M., Kingsman A.J. The expression of hybrid HIV: Ty-virus-like particles in yeast. Nature. 329:1987;68-70.
21. Kingsman S.M., Kingsman A.J. Polyvalent recombinant antigens: a new vaccine strategy. Vaccine. 6:1988;304-306.
22. Griffiths J.C., Berrie E.L., Holdsworth L.N., Moore J.P., Harris S.J., Senior J.M., Kingsman S.M., Kingsman A.J., Adams S.E. Induction of high-titer neutralizing antibodies, using hybrid human immunodeficient virus V-3:Ty-virus-like particles in a clinically relevant adjuvant. J. Virol. 65:1991;450-456.
23. Harris S.E., Gearing A.J.H., Layton G.T., Adams S.E., Kingsman S.M., Kingsman A.J. Enhanced proliferative cellular responses to HIV-1 V-3 peptide and gp120 following immunization with V-3:Ty-virus-like particles. Immunology. 77:1992;315-321.
24. Layton G.T., Harris S.J., Gearing A.J.H., Hill-Perkins M., Cole J.S., Griffiths J.C., Burns N.R., Kingsman A.J., Adams S.E. Induction of HIV-specific cytotoxic T lymphocytes are primed in vivo with hybrid HIV-1 V-3:Ty-virus-like particles. J. Immunol. 151:1993;1097-1107.
25. Weber J., Cheinsong-Popov R., Callow D., Adams S., Patou G., Hodgkin K., Martin S., Gotch F., Kingsman A. Immunogenicity of the yeast recombinant p17/p24:Ty-virus-like particles (p24-VLP) in health volunteers. Vaccine. 13:1995;831-834.
26. Peter B.S., Cheingsong-Popov R., Callow D., Foxall R., Patou G., Hodgkin K., Weber J.N. A pilot phase II study of the safety and immunogenicity of HIV p17/p24: VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J. Infect. 35:1997;231-235.
27. Rodriguez D., Zhou Y.M., Rodriguez J.R., Durbin R.K., Jimenez V., McAllister W.T., Esteban M. Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vector. J. Virol. 64:1990;4851-4857.
28. + T cells using an ELISPOT assay. J. Immunol. Meth. 181:1995;45-54.
29. Arreaza G., Corridor V., Zavala F. Plasmodium yoelii quantification of exoerythrocytic stages based on the use of ribosomal RNA probes. Exp. Parasitol. 72:1989;103-105.
30. Chomczynki P., Sacchi N. Single step method of RNA isolation by guanidiniun thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
31. Layton G.T., Harris S.J., Myhan J., West D., Gotch F., Hill-Perkins M., Cole J.S., Meyers N., Woodrow S., French T.J., Adams S.E., Kingsman A.J. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology. 87:1996;171-178.
32. + T cell responses induced by recombinant influenza and vaccinia viruses. Cell. Immunol. 173:1996;96-107.
33. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., Becker M., Smith G., Butcher G., Sinden R.E., Hill A. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 28:1998;4345-4355.